Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | May 18, 2011 | May 19, 2011 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director · 10% owner | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date May 18, 2011 · Filed May 19, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2011-05-18 transaction · row 1
1 source rowRow 1 · 2011-05-18 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.09 · Expires 2015-05-20 | Direct | 0 |
Reported balance
After 2011-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-05-18 · Exercise / conversion · Disposed 1,000 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 12,495 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 12,495 · Balance 12,495 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member of Spouse | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 31,000 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Achaogen, Inc.
Report date March 18, 2019 · Filed March 20, 2019
Section 16 reporting ended · disclosed 2019-03-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 5,555,414 |
Ending reported balance
After 2019-03-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-18 · Sale · Disposed 271,879 · Balance 6,561,423 Row 2 · 2019-03-19 · Sale · Disposed 956,009 · Balance 5,605,414 Row 3 · 2019-03-20 · Sale · Disposed 50,000 · Balance 5,555,414 |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 30,000 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,000 F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 100,255 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100,255 F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 72,170 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 72,170 F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director.
F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President.
F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2018 Filed Apr 5, 2018 01:25 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 47,361 | $12.44 | $588,976.66 |
DisclosureSEC source: 0000921895-18-001210 · form406922005_04042018.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,482,569 Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 01:25 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 24,100 | $12.46 | $300,240.21 |
DisclosureSEC source: 0000921895-18-001210 · form406922005_04042018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,435,208 Read SEC document |
| April 02, 2018 Filed Apr 5, 2018 01:25 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 20,000 | $12.51 | $250,202.00 |
DisclosureSEC source: 0000921895-18-001210 · form406922005_04042018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,411,108 Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 23:18 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 30,000 | $12.44 | $373,095.00 |
DisclosureSEC source: 0000921895-18-001121 · form406922005_03302018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,391,108 Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 22:39 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 25,000 | $11.09 | $277,155.00 |
DisclosureSEC source: 0000921895-18-001045 · form406922005_03212018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,361,108 Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 22:39 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 11,300 | $11.20 | $126,556.61 |
DisclosureSEC source: 0000921895-18-001045 · form406922005_03212018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,336,108 Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 21:04 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 30,000 | $11.23 | $336,756.00 |
DisclosureSEC source: 0000921895-18-001003 · form406922005_03162018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,324,808 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:04 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 19,660 | $11.57 | $227,487.83 |
DisclosureSEC source: 0000921895-18-001003 · form406922005_03162018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,294,808 Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 22:38 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 20,000 | $11.39 | $227,802.00 |
DisclosureSEC source: 0000921895-18-000962 · form406922005_03132018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,275,148 Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:38 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 50,000 | $11.41 | $570,520.00 |
DisclosureSEC source: 0000921895-18-000962 · form406922005_03132018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,255,148 Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 23:44 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 96,790 | $10.14 | $981,682.90 |
DisclosureSEC source: 0000921895-18-000825 · form406922005_03022018.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,205,148 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 23:44 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 410,606 | $10.33 | $4,243,284.53 |
DisclosureSEC source: 0000921895-18-000825 · form406922005_03022018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,108,358 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 23:44 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 20,000 | $10.70 | $213,928.00 |
DisclosureSEC source: 0000921895-18-000825 · form406922005_03022018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697,752 Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 22:43 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 9,442 | $10.96 | $103,487.15 |
DisclosureSEC source: 0000921895-18-000704 · form406922005_02152018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,677,752 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:43 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 558 | $10.97 | $6,118.69 |
DisclosureSEC source: 0000921895-18-000704 · form406922005_02152018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,668,310 Read SEC document |
| January 05, 2018 Filed Jan 5, 2018 23:03 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 50,000 | $11.51 | $575,500.00 |
DisclosureSEC source: 0000921895-18-000092 · form406922005_01052018.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667,752 Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 23:03 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 15,000 | $10.89 | $163,353.00 |
DisclosureSEC source: 0000921895-18-000092 · form406922005_01052018.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,617,752 Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:07 UTC | Achaogen, Inc. AKAO · Entity 158957 | PurchaseCommon Stock, par value $0.001 per share | 95,012 | $11.13 | $1,057,493.06 |
DisclosureSEC source: 0000921895-17-002933 · form406922005_12202017.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,602,752 Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 02:49 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 20,556 | $22.44 | $461,276.64 |
DisclosureSEC source: 0001209191-17-065527 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,841,069 Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:42 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $23.08 | $0.00 |
DisclosureSEC source: 0001209191-17-059423 · doc4.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-11-02 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option will vest on November 2, 2018, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 20:43 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 22,901 | $22.79 | $521,867.99 |
DisclosureSEC source: 0001209191-17-057753 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,820,513 F1 · price: This is the weighted average purchase price of the shares, which ranged from $22.68 to $22.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 24, 2017 Filed Sep 26, 2017 22:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 2,000,000 | $15.02 | $30,040,000.00 |
DisclosureSEC source: 0001209191-17-054063 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,797,612 Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 7,497 | $15.50 | $116,175.01 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 9 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,797,612 F9 · price: This is the weighted average purchase price of the shares, which ranged from $15.4463 to $15.569 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 23,703 | $15.12 | $358,282.70 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,790,115 F8 · price: This is the weighted average purchase price of the shares, which ranged from $14.4015 to $15.3999 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 500 | $16.22 | $8,107.50 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,766,412 F7 · price: This is the weighted average purchase price of the shares, which ranged from $16.195 to $16.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 125,000 | $15.70 | $1,963,087.50 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,765,912 F6 · price: This is the weighted average purchase price of the shares, which ranged from $15.18 to $16.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 71,598 | $14.38 | $1,029,514.80 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,640,912 F5 · price: This is the weighted average purchase price of the shares, which ranged from $14.16 to $15.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 47,450 | $14.57 | $691,332.27 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,569,314 F4 · price: This is the weighted average purchase price of the shares, which ranged from $14.265 to $15.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 53,820 | $13.90 | $748,135.67 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,521,864 F3 · price: This is the weighted average purchase price of the shares, which ranged from $13.255 to $14.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 30,050 | $12.77 | $383,858.70 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,468,044 F2 · price: This is the weighted average purchase price of the shares, which ranged from $12.14 to $13.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 19, 2017 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 50,300 | $11.66 | $586,608.66 |
DisclosureSEC source: 0001209191-17-053232 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,437,994 F1 · price: This is the weighted average purchase price of the shares, which ranged from $11.1366 to $12.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 03, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 68,964 | $23.70 | $1,634,722.66 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,387,694 F8 · price: This is the weighted average purchase price of the shares, which ranged from $23.121 to $23.916 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 38,290 | $25.12 | $961,883.09 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,318,730 F7 · price: This is the weighted average purchase price of the shares, which ranged from $24.89 to $25.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 14,710 | $24.37 | $358,512.12 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,280,440 F6 · price: This is the weighted average purchase price of the shares, which ranged from $23.885 to $24.88 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 6,868 | $24.02 | $164,955.62 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,265,730 F5 · price: This is the weighted average purchase price of the shares, which ranged from $24.00 to $24.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 80,618 | $23.48 | $1,892,588.17 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,258,862 F4 · price: This is the weighted average purchase price of the shares, which ranged from $22.998 to $23.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 8,000 | $22.75 | $181,984.00 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,178,244 F3 · price: This is the weighted average purchase price of the shares, which ranged from $21.94 to $22.939 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 17,010 | $20.95 | $356,274.45 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,244 F2 · price: This is the weighted average purchase price of the shares, which ranged from $20.646 to $21.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 23:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 42,990 | $20.20 | $868,398.00 |
DisclosureSEC source: 0001209191-17-047540 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,153,234 F1 · price: This is the weighted average purchase price of the shares, which ranged from $19.64 to $20.626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 23, 2017 Filed May 25, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 2,000 | $28.07 | $56,148.00 |
DisclosureSEC source: 0001209191-17-035160 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,110,244 F5 · price: This is the weighted average purchase price of the shares, which ranged from $28.035 to $28.182 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 23, 2017 Filed May 25, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 28,600 | $27.63 | $790,160.80 |
DisclosureSEC source: 0001209191-17-035160 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,108,244 F4 · price: This is the weighted average purchase price of the shares, which ranged from $27.19 to $28.014 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 23, 2017 Filed May 25, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 18,600 | $26.69 | $496,396.80 |
DisclosureSEC source: 0001209191-17-035160 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,079,644 F3 · price: This is the weighted average purchase price of the shares, which ranged from $26.172 to $27.082 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 22, 2017 Filed May 25, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 6,800 | $26.67 | $181,335.60 |
DisclosureSEC source: 0001209191-17-035160 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,061,044 F2 · price: This is the weighted average purchase price of the shares, which ranged from $26.46 to $26.819 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 22, 2017 Filed May 25, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 27,928 | $26.15 | $730,289.27 |
DisclosureSEC source: 0001209191-17-035160 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,054,244 F1 · price: This is the weighted average purchase price of the shares, which ranged from $25.45 to $26.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 11, 2017 Filed May 11, 2017 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 7,500 | $21.52 | $161,377.50 |
DisclosureSEC source: 0001209191-17-031602 · doc4.xml · nonDerivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,026,316 F4 · price: This is the weighted average purchase price of the shares, which ranged from $21.47 to $21.737 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 11, 2017 Filed May 11, 2017 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,100 | $20.55 | $207,544.90 |
DisclosureSEC source: 0001209191-17-031602 · doc4.xml · nonDerivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,018,816 F3 · price: This is the weighted average purchase price of the shares, which ranged from $20.451 to $20.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 19,489 | $21.47 | $418,350.87 |
DisclosureSEC source: 0001209191-17-031602 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,008,716 F2 · price: This is the weighted average purchase price of the shares, which ranged from $21.153 to $21.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 5,000 | $20.07 | $100,360.00 |
DisclosureSEC source: 0001209191-17-031602 · doc4.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,989,227 Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,300 | $19.43 | $25,256.40 |
DisclosureSEC source: 0001209191-17-031602 · doc4.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984,227 F1 · price: This is the weighted average purchase price of the shares, which ranged from $18.98 to $19.95 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 02, 2017 Filed May 3, 2017 00:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 5,000 | $23.40 | $117,000.00 |
DisclosureSEC source: 0001209191-17-029465 · doc4.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,982,927 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.